MA42641A1 - Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih - Google Patents

Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih

Info

Publication number
MA42641A1
MA42641A1 MA42641A MA42641A MA42641A1 MA 42641 A1 MA42641 A1 MA 42641A1 MA 42641 A MA42641 A MA 42641A MA 42641 A MA42641 A MA 42641A MA 42641 A1 MA42641 A1 MA 42641A1
Authority
MA
Morocco
Prior art keywords
trispecific
binding proteins
prevention
treatment
hiv infection
Prior art date
Application number
MA42641A
Other languages
English (en)
Inventor
Huawei Qiu
Christian Beil
Jochen Beninga
Christian Lange
Ercole Rao
Jochen Kruip
Zhi-Yong Yang
Gary Nabel
Ling Xu
Ronnie Wei
Wulf Leuschner
Mark Connors
John Mascola
Richard Koup
Jinghe Huang
Nicole Doria-Rose
Tongqing Zhou
Peter Kwong
Young Kwon
Amarendra Pegu
Mangaiarkarasi Asokan
Original Assignee
Sanofi Sa
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Us Health filed Critical Sanofi Sa
Publication of MA42641A1 publication Critical patent/MA42641A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6881—Cluster-antibody conjugates, i.e. the modifying agent consists of a plurality of antibodies covalently linked to each other or of different antigen-binding fragments covalently linked to each other
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions comprenant des protéines de liaison trispecifiques et/ou trivalentes comprenant quatre chaînes polypeptidiques qui forment trois sites de liaison à l'antigène qui se lient spécifiquement à une ou plusieurs protéines cibles du vih ou un ou plusieurs récepteurs des lymphocytes t, une première paire de polypeptides qui forme la protéine de liaison possédant des domaines variables doubles ayant une orientation croisée et une seconde paire de polypeptides qui forme la prot
MA42641A 2016-02-24 2016-10-24 Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih MA42641A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305211 2016-02-24
PCT/US2016/058540 WO2017074878A1 (fr) 2015-10-25 2016-10-24 Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih

Publications (1)

Publication Number Publication Date
MA42641A1 true MA42641A1 (fr) 2019-03-29

Family

ID=55588187

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42641A MA42641A1 (fr) 2016-02-24 2016-10-24 Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih

Country Status (31)

Country Link
US (3) US20190054182A1 (fr)
EP (2) EP3365366B1 (fr)
JP (3) JP7169190B2 (fr)
KR (1) KR102687212B1 (fr)
CN (4) CN116675776A (fr)
AR (1) AR106466A1 (fr)
AU (2) AU2016347058B2 (fr)
BR (1) BR112018008011A2 (fr)
CA (1) CA3002664A1 (fr)
CL (1) CL2018001065A1 (fr)
CO (1) CO2018005337A2 (fr)
CR (1) CR20180288A (fr)
DO (1) DOP2018000102A (fr)
EA (1) EA201891028A1 (fr)
ES (1) ES2894304T3 (fr)
HK (1) HK1253385A1 (fr)
HR (1) HRP20211528T1 (fr)
HU (1) HUE056608T2 (fr)
IL (2) IL301140A (fr)
MA (1) MA42641A1 (fr)
MX (2) MX2018005048A (fr)
MY (1) MY192278A (fr)
PE (1) PE20181167A1 (fr)
PH (1) PH12018500873A1 (fr)
PL (1) PL3365366T3 (fr)
RS (1) RS62437B1 (fr)
SG (1) SG11201803324VA (fr)
SI (1) SI3365366T1 (fr)
TW (2) TWI750139B (fr)
UY (1) UY36965A (fr)
WO (1) WO2017074878A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048770A2 (fr) 2013-09-30 2015-04-02 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
EP3778630A1 (fr) * 2014-02-28 2021-02-17 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Anticorps monoclonaux largement neutralisant contre la région env vih-1 v1v2
BR112018008011A2 (pt) 2015-10-25 2018-10-30 Sanofi proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
CA3003878A1 (fr) 2015-11-03 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants diriges contre la proteine gp41 du vih-1 et leur utilisation
JP7195929B2 (ja) * 2016-04-13 2022-12-26 サノフイ 三重特異性および／または三価結合タンパク質
ES2960329T3 (es) * 2016-04-13 2024-03-04 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes
WO2017189964A2 (fr) 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions pour le traitement de maladies
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018237148A1 (fr) * 2017-06-21 2018-12-27 Gilead Sciences, Inc. Anticorps multispécifiques ciblant gp120 et cd3 du vih
WO2019074973A2 (fr) 2017-10-10 2019-04-18 Sanofi Anticorps anti-cd38 et procédés d'utilisation
AU2018399587A1 (en) * 2017-12-21 2020-07-09 The Trustees Of Columbia University In The City Of New York Bispecific HIV-1-neutralizing antibodies
BR112020013325A2 (pt) 2018-01-12 2020-12-01 Genzyme Corporation métodos para quantificação de polipeptídeos
EP3797118A4 (fr) 2018-05-22 2022-06-29 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
AU2019357467A1 (en) * 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
WO2020106713A1 (fr) * 2018-11-21 2020-05-28 Beth Israel Deaconess Medical Center, Inc. Traitements par anticorps pour le virus de l'immunodéficience humaine (vih)
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療ｈｉｖ感染之三特異性及／或三價結合蛋白
AU2020272839A1 (en) 2019-04-09 2021-12-02 Sanofi Trispecific binding proteins, methods, and uses thereof
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
JP2022553716A (ja) 2019-10-25 2022-12-26 サノフイ 多特異性結合タンパク質において鎖誤対合を分析する方法
WO2021203103A2 (fr) * 2020-04-03 2021-10-07 Somasekar Seshagiri Polymorphismes du récepteur ace2 et sensibilité variable aux sras-cov-2, procédés de diagnostic et de traitement
PE20231105A1 (es) * 2020-08-25 2023-07-19 Gilead Sciences Inc Moleculas de union a antigeno multi-especificas contra el vih y metodos de uso
CN118317979A (zh) * 2021-09-29 2024-07-09 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338518C (fr) 1987-09-23 1996-08-13 Joyce M. Zarling Heteroconjugues d'anticorps pour tuer les cellules infectees par le vih
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
KR100927261B1 (ko) 2001-01-17 2009-11-18 트루비온 파마슈티칼스, 인코포레이티드 결합 도메인-면역글로불린 융합 단백질
CN1294148C (zh) 2001-04-11 2007-01-10 中国科学院遗传与发育生物学研究所 环状单链三特异抗体
JP5068072B2 (ja) 2003-06-27 2012-11-07 バイオジェン・アイデック・エムエイ・インコーポレイテッド 連結ペプチドを含む改変された結合分子
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN100376599C (zh) 2004-04-01 2008-03-26 北京安波特基因工程技术有限公司 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体
EP2014680A1 (fr) * 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Dérivés d'anticorps bi-spécifiques ou tri-spécifiques trivalents, recombinants, à simple chaîne
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
EP2297209A4 (fr) 2008-06-03 2012-08-01 Abbott Lab Immunoglobulines à deux domaines variables et leurs utilisations
WO2011038290A2 (fr) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants dirigés contre le vih-1 et utilisation associée
DK2580243T3 (da) 2010-06-09 2020-01-13 Genmab As Antibodies against human cd38
JP2014502262A (ja) 2010-11-12 2014-01-30 ザ ロックフェラー ユニバーシティ Ｈｉｖ治療用の融合タンパク質
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
TWI838039B (zh) 2011-03-28 2024-04-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
WO2012154312A1 (fr) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps neutralisants anti-vih-1 et leur utilisation
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
SI2710033T1 (sl) * 2011-05-17 2021-05-31 The Rockefeller University Virus humane imunske pomanjkljivosti nevtralizirajoča protitelesa in metode njihove uporabe
RU2624046C2 (ru) 2011-11-07 2017-06-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретэри, Департмент Оф Хелт Энд Хьюман Сервисиз Gp41-нейтрализующие антитела и их применение
CA2854806A1 (fr) * 2011-11-07 2013-05-16 Medimmune, Llc Proteines de liaison multispecifiques et multivalentes et leurs utilisations
AU2012347453B2 (en) 2011-12-08 2017-11-23 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to HIV-1 and their use
WO2013163427A1 (fr) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps pour traiter les infections par le vih-1
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
IN2015MN00139A (fr) * 2012-09-25 2015-10-16 Glenmark Pharmaceuticals Sa
CN104955847A (zh) 2012-12-04 2015-09-30 马里兰州大学(巴尔的摩) HIV-1 Env结合抗体、融合蛋白及其使用方法
KR20150093834A (ko) 2012-12-13 2015-08-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Ｄｎａ 항체 작제물 및 그 이용 방법
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
WO2014116846A2 (fr) * 2013-01-23 2014-07-31 Abbvie, Inc. Procédés et compositions pour moduler une réponse immunitaire
KR102282761B1 (ko) 2013-02-26 2021-07-30 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
AU2014227664A1 (en) 2013-03-15 2015-09-24 Abbvie Inc. Dual specific binding proteins directed against TNFalpha
CA2954168C (fr) 2013-08-02 2023-09-19 The Regents Of The University Of California Modification d'une immunite antivirale mediee par les cellules t par des cellules souches et des recepteurs d'antigene chimeriques
AU2014343636A1 (en) 2013-11-04 2016-06-02 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
US9822186B2 (en) 2014-03-28 2017-11-21 Xencor, Inc. Bispecific antibodies that bind to CD38 and CD3
US10961506B2 (en) 2014-09-04 2021-03-30 Stemcell Technologies Inc. Soluble antibody complexes for T cell or NK cell activation and expansion
WO2016116626A1 (fr) 2015-01-23 2016-07-28 Sanofi Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
BR112017024573B1 (pt) 2015-05-20 2024-03-05 Quantum-Si Incorporated Método de identificação de uma molécula única em uma amostra
US10654943B2 (en) 2015-06-02 2020-05-19 The Rockefeller University Tri-specific antibodies for HIV therapy
US10738099B2 (en) 2015-09-22 2020-08-11 The Trustees Of The University Of Pennsylvania Method of redirecting T cells to treat HIV infection
BR112018008011A2 (pt) 2015-10-25 2018-10-30 Sanofi proteínas de ligação triespecíficas e/ou trivalentes para prevenção ou tratamento de infecção por hiv
CN105837688B (zh) 2015-11-20 2019-02-26 北京大学深圳研究生院 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞
MA44077A (fr) 2015-12-15 2021-05-05 Gilead Sciences Inc Anticorps neutralisants le virus de l'immunodéficience humaine
JP7195929B2 (ja) 2016-04-13 2022-12-26 サノフイ 三重特異性および／または三価結合タンパク質
ES2960329T3 (es) 2016-04-13 2024-03-04 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes
EP3575319A4 (fr) 2016-12-30 2021-03-10 Shanghai Sinobio Biotech Co., Ltd. Molécule bifonctionnelle et son utilisation
US10626169B2 (en) 2017-02-17 2020-04-21 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
JP7304288B2 (ja) 2017-02-17 2023-07-06 サノフイ ジストログリカンおよびラミニン２に対する特異性を有する多特異性結合性分子
US11845787B2 (en) 2017-03-27 2023-12-19 The Wistar Institute Of Anatomy And Biology DNA antibody constructs for use against HIV
WO2019074973A2 (fr) 2017-10-10 2019-04-18 Sanofi Anticorps anti-cd38 et procédés d'utilisation
AU2019357467A1 (en) 2018-10-09 2021-05-27 Sanofi Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof

Also Published As

Publication number Publication date
SI3365366T1 (sl) 2022-02-28
EP3819310A1 (fr) 2021-05-12
WO2017074878A1 (fr) 2017-05-04
KR20180063336A (ko) 2018-06-11
PE20181167A1 (es) 2018-07-19
HRP20211528T1 (hr) 2021-12-24
CR20180288A (es) 2018-09-11
PH12018500873A1 (en) 2018-11-12
CL2018001065A1 (es) 2018-11-23
EA201891028A1 (ru) 2019-02-28
IL258822A (en) 2018-06-28
EP3365366A1 (fr) 2018-08-29
SG11201803324VA (en) 2018-05-30
AU2016347058B2 (en) 2023-11-09
MY192278A (en) 2022-08-16
CN116675776A (zh) 2023-09-01
BR112018008011A2 (pt) 2018-10-30
US11129905B2 (en) 2021-09-28
EP3365366B1 (fr) 2021-07-14
JP2021072847A (ja) 2021-05-13
CO2018005337A2 (es) 2018-07-10
US11779651B2 (en) 2023-10-10
CN116789841A (zh) 2023-09-22
RS62437B1 (sr) 2021-11-30
MX2022014631A (es) 2023-01-11
TW201730210A (zh) 2017-09-01
TWI750139B (zh) 2021-12-21
TW202219064A (zh) 2022-05-16
CN109311966B (zh) 2023-03-10
UY36965A (es) 2017-05-31
KR102687212B1 (ko) 2024-07-19
AU2024200395A1 (en) 2024-04-11
NZ742825A (en) 2024-04-26
HK1253385A1 (zh) 2019-06-14
CA3002664A1 (fr) 2017-05-04
JP7169190B2 (ja) 2022-11-10
MX2018005048A (es) 2018-09-06
JP2023085476A (ja) 2023-06-20
CN117069855A (zh) 2023-11-17
US20220226495A1 (en) 2022-07-21
ES2894304T3 (es) 2022-02-14
JP7328267B2 (ja) 2023-08-16
WO2017074878A8 (fr) 2018-05-24
PL3365366T3 (pl) 2022-01-31
AR106466A1 (es) 2018-01-17
JP2018537966A (ja) 2018-12-27
AU2016347058A1 (en) 2018-06-14
IL258822B2 (en) 2023-08-01
HUE056608T2 (hu) 2022-02-28
IL301140A (en) 2023-05-01
CN109311966A (zh) 2019-02-05
IL258822B1 (en) 2023-04-01
US20200054765A1 (en) 2020-02-20
US20190054182A1 (en) 2019-02-21
DOP2018000102A (es) 2018-11-30

Similar Documents

Publication Publication Date Title
MA42641A1 (fr) Protéines de liaison trispécifiques et/ou trivalentes pour la prévention ou le traitement d'une infection par le vih
MA44670B1 (fr) Protéines de liaison trispécifiques et/ou trivalentes
MA40801A1 (fr) Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123
WO2018050902A3 (fr) Multimères, tétramères et octamères
MX2022015847A (es) Proteinas de union a cd123 y composiciones y metodos relacionados.
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2022016192A (es) Anticuerpos anti-nectina-4 condicionalmente activos.
MA39342B2 (fr) Anticorps il -21
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
MA54975B1 (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202092458A1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
WO2021024133A3 (fr) Compositions biopharmaceutiques et procédés associés
MX2022003911A (es) Anticuerpo, composicion farmaceutica y metodo.
MX2023004804A (es) Proteinas de union triespecificas y/o trivalentes.
BR112021019915A2 (pt) Proteínas de ligação triespecíficas, métodos e usos dos mesmos
EA202192488A1 (ru) Антитела против tsg-6 и их применения
EA202092593A1 (ru) Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
MA54501A (fr) Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
MX2021003867A (es) Anticuerpo monoclonal beta amiloide anti-n-truncado humanizado.
MA55609A (fr) Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih
MX2022006632A (es) Anticuerpos ampliamente neutralizantes contra el vih.
EA202092229A1 (ru) Мутеины cd4 и способы их применения
MA48870B1 (fr) Anticorps anti-sortiline et leurs méthodes d'utilisation
EA201992324A1 (ru) Анти-trem2 антитела и способы их применения